Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00140725 |
This is a single-centre prospective randomised study comparing the virological and histological response of HBV infection to lamivudine in combination with interferon versus lamivudine alone.
Condition | Intervention | Phase |
---|---|---|
Chronic Hepatitis B |
Drug: Lamivudine plus Polyethylene glyco-interferon alfa-2b Drug: Lamivudine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomised Trial of Lamivudine Plus Interferon Versus Lamivudine for the Treatment of HBeAg Positive Chronic Hepatitis B Virus (HBV) |
Estimated Enrollment: | 160 |
Study Start Date: | April 2000 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | NUC30938 |
Study First Received: | August 31, 2005 |
Last Updated: | October 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00140725 |
Health Authority: | Hong Kong: Department of Health |
HBeAg-positive chronic Hepatitis B |
lamivudine seroconversion Chronic Hepatitis B |
Interferon-alpha Liver Diseases Hepatitis, Chronic Interferons Hepatitis, Viral, Human Lamivudine Hepatitis |
Virus Diseases Digestive System Diseases Hepatitis B, Chronic Hepatitis B DNA Virus Infections Interferon Alfa-2a Interferon Alfa-2b |
Anti-Infective Agents Anti-HIV Agents Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Growth Substances Physiological Effects of Drugs Enzyme Inhibitors Hepadnaviridae Infections |
Antiviral Agents Angiogenesis Inhibitors Pharmacologic Actions Reverse Transcriptase Inhibitors Anti-Retroviral Agents Therapeutic Uses Angiogenesis Modulating Agents Growth Inhibitors Nucleic Acid Synthesis Inhibitors |